Results 1 to 10 of about 316,300 (296)

A comparison of poly(methyl methacrylate) and silorane-based cements as carriers for local doxorubicin delivery [PDF]

Journal of Materials Science: Materials in Medicine
Orthopedic osteosarcomas and metastatic lesions can be difficult to treat with systemically delivered chemotherapy agents alone. Following removal of the primary tumor, implantation of cement to fill the lesion is often done to stabilize weight-bearing ...
Grahmm A. Funk, Elizabeth M. Menuey, Zachary D. Denton, Dalan M. Pittz, Alejandro Parrales, Tomoo Iwakuma, Kathleen V. Kilway, Terence E. McIff   +7 more
doaj   +2 more sources

Engineered microalgal extracellular vesicles for efficient doxorubicin delivery and improved therapeutic efficacy in breast cancer [PDF]

Materials Today Bio
Extracellular vesicles (EVs) have emerged as versatile and biocompatible nanocarriers for drug delivery, offering significant advantages over synthetic nanoparticles, which often suffer from rapid clearance, immunogenicity, and limited clinical ...
Giorgia Adamo, Sabrina Picciotto, Pamela Santonicola, Paola Gargano, Estella Rao, Angela Paterna, Samuele Raccosta, Giulia Smeraldi, Carolina Paganini, Daniele P. Romancino, Monica Salamone, Claudio Russo, Paolo Arosio, Elia Di Schiavi, Mauro Manno, Antonella Bongiovanni   +15 more
doaj   +2 more sources

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity

Anatolian Journal of Cardiology, 2023
Background: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use.
Sebahat Ulusan, Kanat Gülle, Ahmet Peynirci, Murat Sevimli, Adnan Karaibrahimoglu, Mevlüt Serdar Kuyumcu   +5 more
doaj   +1 more source

IFN-γ/Doxorubicin Complex Nanoparticles for Enhancing Therapy in the Context of Human Ovarian Carcinoma

Frontiers in Materials, 2022
The cytokine interferon gamma (IFN-γ) and doxorubicin mono-therapy has been approved by the Food and Drug Administration (FDA) for the treatment of tumors.
Rongyuan Yi, Wanwan Lv, Shan Zheng, Ningyu Zhang, Yuheng Zhang, Kai Yang, Tuo Huang, Yanning Yang, Hui Chu, Jian Chen   +9 more
doaj   +1 more source

Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity

Frontiers in Cardiovascular Medicine, 2021
Doxorubicin causes cardiotoxicity and exercise intolerance. Pre-conditioning exercise training seems to prevent doxorubicin-induced cardiac damage.
Igor L. Gomes-Santos, Camila P. Jordão, Clevia S. Passos, Patricia C. Brum, Edilamar M. Oliveira, Roger Chammas, Anamaria A. Camargo, Carlos E. Negrão, Carlos E. Negrão   +8 more
doaj   +1 more source

Royal Jelly Alleviates Side Effects of Doxorubicin on Male Reproductive System: A Mouse Model Simulated Human Chemotherapy Cycles [PDF]

Research Journal of Pharmacognosy, 2022
Background and objectives: Doxorubicin, an effective anticancer agent, might impair the function of testicular tissue and lead to infertility. Royal jelly can heal male infertility because of its antioxidant activities.
Mansour Safaei Pourzamani, Shahrbanoo Oryan, Parichehr Yaghmaei, Cyrus Jalili, Ali Ghanbari*   +4 more
doaj   +1 more source

Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity

JACC. CardioOncology, 2020
Objectives: This study investigated the cardioprotective effect of repeated remote ischemic preconditioning (rRIC) on doxorubicin-induced cardiotoxicity in mice.
Quan He, PhD, Fangfei Wang, MD, Thomas D. Ryan, PhD, MD, Meghana Chalasani, BS, Andrew N. Redington, MD   +4 more
doaj   +1 more source

Doxorubicin Cardiomyopathy [PDF]

Cardiology, 2009
Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained.
Kanu, Chatterjee, Jianqing, Zhang, Norman, Honbo, Joel S, Karliner   +3 more
openaire   +2 more sources

Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin

Biomolecules, 2022
Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells.
Wang Yin, Cuong V. Pham, Tao Wang, Hadi Al Shamaileh, Rocky Chowdhury, Shweta Patel, Yong Li, Lingxue Kong, Yingchu Hou, Yimin Zhu, Sunrui Chen, Huo Xu, Lee Jia, Wei Duan, Dongxi Xiang   +14 more
doaj   +1 more source

Diosmin Alleviates Doxorubicin-Induced Liver Injury via Modulation of Oxidative Stress-Mediated Hepatic Inflammation and Apoptosis via NfkB and MAPK Pathway: A Preclinical Study

Antioxidants, 2021
Hepatotoxicity caused by chemotherapeutic drugs (e.g., doxorubicin) is of critical concern in cancer therapy. This study focused on investigating the modulatory effects of diosmin against doxorubicin-induced hepatotoxicity in Male Wistar rats.
Abdullah F. AlAsmari, Metab Alharbi, Faleh Alqahtani, Fawaz Alasmari, Mohammed AlSwayyed, Sami I. Alzarea, Ibrahim A. Al-Alallah, Adel Alghamdi, Hassan M. Hakami, Meshal K. Alyousef, Youssef Sari, Nemat Ali   +11 more
doaj   +1 more source